Chen Schor - 21 May 2026 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Reporting relationship: Director
Issuer ticker: KPTI
Reported as of: 21 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 May 2026, 16:14:29 UTC
Prior SEC filing: 27 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Nancy Smith, Attorney-in-Fact for Chen Schor

Key filing fact

Chen Schor filed Form 4 for Karyopharm Therapeutics Inc. (KPTI) on 26 May 2026.

Key facts

This page summarizes Chen Schor's Form 4 filing for Karyopharm Therapeutics Inc. (KPTI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 May 2026, 16:14.

Change

Previous filing in this sequence was filed on 27 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001340875 Primary reporting owner

Schor Chen

Relationship: Director
Address: C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON
Signature: /s/ Nancy Smith, Attorney-in-Fact for Chen Schor
Signature date: 26 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KPTI transaction

Common Stock

Award

Transaction value
Shares: +15,508
Change %
Price: $0.000000^*
Shares after: 15,508
Date: 21 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.